Arrowpoint Investment Partners Singapore Pte. Ltd. Buys Shares of 2,855 Biogen Inc. $BIIB

Arrowpoint Investment Partners Singapore Pte. Ltd. bought a new stake in Biogen Inc. (NASDAQ:BIIB) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 2,855 shares of the biotechnology company’s stock, valued at approximately $502,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in BIIB. WPG Advisers LLC raised its position in Biogen by 417.9% in the fourth quarter. WPG Advisers LLC now owns 145 shares of the biotechnology company’s stock valued at $26,000 after purchasing an additional 117 shares during the period. Accredited Wealth Management LLC increased its stake in Biogen by 1,233.3% during the 3rd quarter. Accredited Wealth Management LLC now owns 200 shares of the biotechnology company’s stock worth $28,000 after buying an additional 185 shares during the period. First Horizon Corp purchased a new stake in Biogen during the 4th quarter worth approximately $30,000. WFA of San Diego LLC purchased a new stake in Biogen during the 2nd quarter worth approximately $32,000. Finally, Root Financial Partners LLC increased its stake in Biogen by 198.4% during the 4th quarter. Root Financial Partners LLC now owns 185 shares of the biotechnology company’s stock worth $33,000 after buying an additional 123 shares during the period. Hedge funds and other institutional investors own 87.93% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have commented on the stock. Truist Financial dropped their price target on shares of Biogen from $193.00 to $189.00 and set a “hold” rating for the company in a research note on Monday, April 13th. The Goldman Sachs Group boosted their price target on shares of Biogen from $231.00 to $238.00 and gave the stock a “buy” rating in a research note on Friday, April 24th. Morgan Stanley boosted their price target on shares of Biogen from $200.00 to $206.00 and gave the stock an “equal weight” rating in a research note on Thursday, April 30th. Mizuho boosted their price target on shares of Biogen from $207.00 to $236.00 and gave the stock an “outperform” rating in a research note on Tuesday, February 10th. Finally, Citigroup boosted their price target on shares of Biogen from $190.00 to $200.00 and gave the stock a “neutral” rating in a research note on Friday, May 1st. One research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, thirteen have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $215.81.

Biogen Price Performance

Biogen stock opened at $196.45 on Friday. The stock has a market cap of $29.00 billion, a P/E ratio of 21.08, a price-to-earnings-growth ratio of 1.73 and a beta of 0.20. The company has a fifty day simple moving average of $187.48 and a 200-day simple moving average of $183.24. Biogen Inc. has a 12-month low of $121.05 and a 12-month high of $205.97. The company has a current ratio of 3.06, a quick ratio of 2.41 and a debt-to-equity ratio of 0.34.

Biogen (NASDAQ:BIIB) last released its quarterly earnings data on Wednesday, April 29th. The biotechnology company reported $3.57 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.95 by $0.62. The business had revenue of $2.48 billion during the quarter, compared to analysts’ expectations of $2.29 billion. Biogen had a net margin of 13.81% and a return on equity of 12.83%. The company’s revenue for the quarter was up 1.9% on a year-over-year basis. During the same period in the previous year, the company earned $3.02 EPS. Biogen has set its FY 2026 guidance at 14.250-15.250 EPS. Equities analysts expect that Biogen Inc. will post 14.18 EPS for the current fiscal year.

Biogen News Roundup

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Biogen said the FDA granted Breakthrough Therapy Designation to salanersen for spinal muscular atrophy, based on early data suggesting improved motor function and slower neurodegeneration in some children who had previously received gene therapy. This raises the odds of faster development and potential investor interest in a future SMA treatment. Biogen’s Salanersen Receives FDA Breakthrough Therapy Designation for Spinal Muscular Atrophy
• Positive Sentiment: At EULAR 2026, Biogen and UCB presented additional data on dapirolizumab pegol showing sustained disease control at lower steroid doses and reduced flare rates in systemic lupus erythematosus. The results strengthen the case for a potential steroid-sparing lupus therapy, which could be valuable if development continues to progress. EULAR 2026: Dapirolizumab Pegol Shows Potential to Reduce Flare Rates and Maintain Disease Control in Systemic Lupus Erythematosus
• Positive Sentiment: Biogen also highlighted broad nephrology progress, with 14 accepted abstracts for EMPAVELI and investigational felzartamab across major kidney congresses. The data presentations reinforce the company’s expanding rare-disease pipeline and could help support long-term growth expectations. Biogen Announces Upcoming Kidney Presentations at European Renal Association and American Transplant Congresses
• Neutral Sentiment: Biogen’s kidney presentations included supportive long-term EMPAVELI data and early felzartamab findings, but these are still congress updates rather than new commercial approvals, so the market impact may be limited for now. Biogen Showcases Nephrology Advances with EMPAVELI® and Felzartamab at Major Medical Congresses
• Negative Sentiment: A law firm also announced an investor investigation into Biogen, which can create some headline pressure and caution among traders even though no wrongdoing has been established. INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. – BIIB

Biogen Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.